Since both HER-2 and HER-3 are overexpressed in a relevant proportion of primary CRC and CRC liver metastases, targeting of HER-2 and HER-3 simultaneously may be considered as a potential therapeutic strategy in these patients upon failure of EGFR inhibition. This evidence concerns the gene ERBB2 and colorectal carcinoma.